FoF1-ATP Synthase Tetramer Purification via Surfactant Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge lies in obtaining a highly purified FoF1-ATP synthase enzyme in an intact state, as it is extremely unstable and difficult to purify due to its flexibility and rotation, which is crucial for structural analysis and drug design targeting mitochondrial and immune metabolic diseases.
Innovation Solution
A method involving the purification of FoF1-ATP synthase tetramer using density gradient centrifugation and surfactants like glycodiosgenin, which maintains the enzyme's structure and function, allowing for large-scale production of highly purified enzyme oligomers that can be reconstituted into lipid bilayer membranes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional purification methods are used for FoF1-ATP synthase, then the enzyme can be isolated, but the enzyme loses its structural integrity and function due to instability caused by flexibility and rotation
Solution Approach 1:
The patent uses surfactants as intermediary substances to stabilize the FoF1-ATP synthase enzyme during purification. The surfactants form protective complexes with the enzyme, preventing structural degradation caused by flexibility and rotation, thereby enabling high-purity isolation while maintaining enzyme integrity and function
Solution Approach 2:
The patent employs density gradient centrifugation to separate the enzyme based on density parameters. By adjusting the density gradient conditions and using specific surfactant concentrations, the enzyme can be purified to high precision while maintaining its stable oligomeric state, resolving the contradiction between purification quality and enzyme stability
2Manufacturing precision
If the enzyme is purified to high purity, then structural analysis and drug design become feasible, but the purification process is extremely difficult due to enzyme instability
Solution Approach 1:
Surfactants serve as protective intermediaries that bind to the enzyme and prevent aggregation or degradation during the purification process. This intermediary protection simplifies the purification procedure by maintaining enzyme solubility and stability throughout multiple purification steps, making high-purity isolation achievable despite inherent enzyme instability
Solution Approach 2:
The enzyme's natural oligomeric structure provides self-stabilization properties that are exploited during purification. By maintaining physiological conditions and using gentle purification methods, the enzyme's inherent stability mechanisms are preserved, reducing the complexity of the purification process while achieving high purity
3Reliability
If the enzyme is kept in intact state for structural analysis, then functional studies become possible, but the enzyme cannot be obtained in large quantities due to purification difficulties
Solution Approach 1:
The use of surfactants as protective intermediaries enables scaling up the purification process while maintaining enzyme integrity. The surfactant-enzyme complexes remain stable during large-scale processing, allowing production of sufficient quantities for structural analysis and drug screening without compromising enzyme intact state
Solution Approach 2:
The patent employs preliminary stabilization measures by incorporating surfactants early in the extraction process, before any purification steps are performed. This preliminary protection ensures that the enzyme remains intact throughout subsequent large-scale purification operations, enabling both high integrity and sufficient production quantity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of highly purified FoF1-ATP synthase tetramer in large quantities while preserving its activity and structure, facilitating structural analysis and potential drug design targeting mitochondrial and immune metabolic diseases.
Implementation Method 1
a step of dissolving a biological sample comprising FoF1-ATP synthase with a surfactant
Implementation Method 2
a step of separating the solution obtained in step (1) using density gradient centrifugation
Data Source
AI summary
To provide: a highly purified FoF1-ATP synthase in a large quantity in an intact state; a method for producing said enzyme in a highly purified and intact stateSolution for Solving the ProblemProvided is a purified FoF1-ATP synthase oligomer. Specifically, said oligomer is a tetramer. The method for producing the FoF1-ATP synthase oligomer comprises: (1) a step for lysing, through use of a surfactant, a biological sample containing a FoF1-ATP synthase; (2) a step for performing density gradient centrifugation on the lysate obtained in step (1); and (3) a step for isolating a fraction containing the FoF1-ATP synthase. The surfactant is an anionic surfactant and/or a nonionic surfactant. The density gradient solute used in the density gradient centrifugation is sucrose.